|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Marketable securities | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Unbilled receivables | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Right-of-use assets, net | ||||||||||||||||||||
| In-process research and development asset | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Long-term restricted cash | ||||||||||||||||||||
| Investment | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Long-term prepaid expenses and other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and stockholders’ deficit | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||||
| Loan payable | ||||||||||||||||||||
| Lease liabilities | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Contingent value right liability | ||||||||||||||||||||
| Forward contract liabilities | ||||||||||||||||||||
| Warrant liability | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Loan payable, net of current portion | ||||||||||||||||||||
| Lease liabilities, net of current portion | ||||||||||||||||||||
| Deferred revenue, net of current portion | ||||||||||||||||||||
| Warrant liability | ||||||||||||||||||||
| Warrant liability, net of current portion | ||||||||||||||||||||
| Long-term debt, net | ||||||||||||||||||||
| Contingent value rights liability | ||||||||||||||||||||
| Deferred tax liabilities, net | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Series A Preferred Stock, $0.0001 par value; no and 548,375 shares authorized as of December 31, 2024 and December 31, 2023, respectively; no and 435,120.513 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively | ||||||||||||||||||||
| Options for Series A Preferred Stock | ||||||||||||||||||||
| Stockholders’ deficit: | ||||||||||||||||||||
| Preferred stock, value, issued | ||||||||||||||||||||
| Series A Preferred Stock | ||||||||||||||||||||
| Series B Preferred Stock | ||||||||||||||||||||
| Total preferred stock, value, issued | ||||||||||||||||||||
| Common stock, $0.0001 par value; 350,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 30,037,962 and 26,011,106 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total stockholders’ deficit | ||||||||||||||||||||
| Total liabilities and stockholders’ deficit | ||||||||||||||||||||
| Common Stock, Shares Authorized | ||||||||||||||||||||
Loading...
